<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50279">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01917929</url>
  </required_header>
  <id_info>
    <org_study_id>75</org_study_id>
    <nct_id>NCT01917929</nct_id>
  </id_info>
  <brief_title>Secur-Fit Advanced Outcomes Study</brief_title>
  <official_title>A Prospective, Post-market, Multi-center Evaluation of the Clinical Outcomes of the Secur-Fit Advanced Hip Stem</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stryker Orthopaedics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stryker Orthopaedics</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, open-label, post-market, non-randomized, multi-center clinical
      evaluation of the Secur-Fit Advanced Hip Stem for primary total hip arthroplasty with a
      cementless application in a consecutive series of patients who meet the eligibility
      criteria.  The success rate of the Secur-Fit Advanced femoral stem, defined as absence of
      stem revision for aseptic loosening or femoral fracture, is expected to be no worse than 99%
      at 5 years postoperative with a non-inferiority margin of 2.5%.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">November 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Rate of revision for aseptic loosening or femoral fracture</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause revision and removal rate</measure>
    <time_frame>10 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of femoral fracture</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">326</enrollment>
  <condition>Arthroplasty, Replacement, Hip</condition>
  <arm_group>
    <arm_group_label>Secur-Fit Advanced</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Secur-Fit Advanced Hip Stem</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Secur-Fit Advanced Hip Stem</intervention_name>
    <description>Straight femoral stem intended for cementless, press-fit application.</description>
    <arm_group_label>Secur-Fit Advanced</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has signed an Institutional Review Board (IRB)/Ethics Committee (EC)
             approved, study specific Informed Patient Consent Form.

          -  Patient is a male or non-pregnant female, skeletally mature and age 21-75 years at
             time of study device implantation.

          -  Patient has a diagnosis of Non-Inflammatory Degenerative Joint Disease.

          -  Patient is a candidate for primary total hip arthroplasty.

          -  Patient is willing and able to comply with postoperative scheduled clinical and
             radiographic evaluations and rehabilitation.

        Exclusion Criteria:

          -  Patient has previously undergone open surgical intervention on the operative hip.

          -  Patient has a prior femoral fracture, with or without deformity, on the operative
             side.

          -  Patient has an existing total hip replacement on the contralateral side.

          -  Patient requires simultaneous bilateral total hip replacement.

          -  Patient has a Body Mass Index (BMI) &gt; 45.

          -  Patient has an active or suspected latent infection in or about the affected hip
             joint at time of study device implantation.

          -  Patient has a neuromuscular or neurosensory deficiency that would create an
             unacceptable risk of instability, prosthesis fixation failure or complications in
             postoperative care, or which limits the ability to evaluate the safety and efficacy
             of the device.

          -  Patient has bone stock that is inadequate for support or fixation of the prosthesis,
             or is diagnosed with a systemic disease (e.g. Lupus Erythematosus) or a metabolic
             disorder (e.g. Paget's disease) leading to progressive bone deterioration.

          -  Patient is immunologically suppressed or receiving steroids in excess of normal
             physiological requirements (e.g. &gt; 30 days).

          -  Patient has a known sensitivity to device materials.

          -  Patient is a prisoner.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alice Cruz</last_name>
    <phone>201-831-5859</phone>
    <email>alice.cruz@stryker.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Catherine Vanacore</last_name>
    <phone>201-831-5893</phone>
    <email>catherine.vanacore@stryker.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tucson Orthopaedic Institute</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crystal Placencia</last_name>
      <phone>520-784-6430</phone>
      <email>cplacencia@tucsonortho.com</email>
    </contact>
    <investigator>
      <last_name>Russell Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Family Orthopedic Center</name>
      <address>
        <city>Spring Valley</city>
        <state>Illinois</state>
        <zip>61362</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colette Andreoni</last_name>
      <phone>815-663-8009</phone>
      <email>CAndreoni@aboutsmh.org</email>
    </contact>
    <investigator>
      <last_name>Paul Perona, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Boles</last_name>
      <phone>212-639-9266</phone>
      <email>bolesj@hss.edu</email>
    </contact>
    <investigator>
      <last_name>Geoffrey Westrich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Friend</last_name>
      <phone>919-668-4373</phone>
      <email>jennifer.friend@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Samuel Wellman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 27, 2014</lastchanged_date>
  <firstreceived_date>June 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>[E04.555.110.110.110]</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
